GlaxoSmithKline/Adolor Halt Entereg Bowel Dysfunction Program Due To Cardiovascular Events
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-line, 12-month Phase III safety data underscore CV concerns and raise new adverse event questions.